Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Obesity Week 2023Beyond Semaglutide, a Coming Pipeline of New Antiobesity MedsWith nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are in sight.
Medscape Medical News, October 31, 2023
Obesity Week 2023Antidepressants 'Don't Blunt' Semaglutide and Weight LossClinicians 'should be reassured' that patients with obesity and on antidepressants who don't have major depressive disorder or suicidality in the past 2 years can receive semaglutide, says a researcher.
Tirzepatide Lowers Weight Across All Groups With ObesityThe anti-obesity medication semaglutide (Wegovy) 'took things up one big notch, and now tirzepatide [which is still awaiting
approval for weight loss] is up a little notch above that,' one expert commented.